Ablative fractional Co2 laser aided delivery of long-acting glucocorticoid in the treatment of acral vitiligo: a multicenter, prospective, self-bilateral controlled study
Ablative fractional Co2 laser aided delivery of long-acting glucocorticoid in the treatment of acral vitiligo: a multicenter, prospective, self-bilateral controlled study
复制标题
烧蚀点阵 Co2 激光辅助长效糖皮质激素治疗肢端白癜风：一项多中心、前瞻性、自我双边对照研究
DOI：
10.1080/09546634.2018.1509048
复制
发表时间：
2018-10
影响因子：
2.9
通讯作者：
Xing Hua Gao
中科院分区：
文献类型：
--
作者：
Ling Liu;Yan Wu;Jianzhong Zhang;Heng Gu;Qi Luan;Linhan Qian;Yanting Wang;Lin Gao;Hongyi Wang;Bihuan Xiao;Yan Sun;Houmin Li;Kun Chen;Fanqin Zeng;Chunying Li;Tianwen Gao;Xing Hua Gao
摘要背景：肢端白癜风往往反应不佳的治疗。目的：目的：观察分数CO2激光辅助复方倍他米松溶液联合NB-UVB透皮治疗顽固性肢端白癜风的疗效。方法：研究对象为对称性、稳定性肢端白癜风患者。将对称的病变随机分配到受试者的实验侧和对照侧。实验侧接受5次间隔1个月的分数CO2激光消融治疗，然后局部涂抹复方倍他米松溶液1次，对照侧局部涂抹倍他米松乳膏1次/d;两侧均接受NB-UVB治疗，每周3次。在第1次、第2次、第3次和第5次治疗后1个月进行评估。结果：289例受试者进入临床试验，126例受试者完成研究。实验侧表现出更好的改善，在色素沉着。总有效率（色素恢复率≥10%）实验侧为51.6%，对照侧为35.8%。试验期间所有受试者均未发生严重不良事件。结论：结论：CO_2激光联合复方倍他米松溶液及NB-UVB治疗肢端白癜风安全性高，值得临床推广应用。临床试验注册：本临床试验已在中国临床试验注册中心注册（注册号：ChiCTR-TRC-12002593）
Abstract Background: Acral vitiligo often responses poorly to treatments. Objective: To observe whether pretreatment with ablative fractional CO2 laser aiding penetration of compound betamethasone solution plus NB-UVB could improve the response of refractory acral vitiligo. Methods: Subjects with symmetrical and stable acral vitiligo were enrolled in this study. The symmetrical lesions were randomly allocated to experimental and control sides in a subject. The experimental side underwent five sessions, one month apart, of ablative fractional CO2 laser followed by once of a topical painting of compound betamethasone solution, the control side applied topical betamethasone cream once a day; both sides underwent NB-UVB three times per week. The assessment was performed one month following each of the 1st, 2nd, 3rd, and 5th treatment sessions. Results: Two hundred eighty-nine subjects entered the clinical trial and 126 subjects completed the study. The experiment side showed better improvement in repigmentation. Overall response rate (repigmentation percentage ≥10%) of experiment sides was 51.6%, in contrast, that of control side was 35.8%. There were no severe adverse events in all subjects during the trial. Conclusions: A triple method of ablative fractional CO2 laser, topical compound betamethasone solution plus NB-UVB provided an alternative choice for acral vitiligo with remarkable safety profile. Cinical trial registration: This clinical trial has been registered at Chinese Clinical Trial Registry (Registration number: ChiCTR-TRC-12002593)
登录
查看更多内容
影响因子：
10.3
作者：
Ongenae, K;Van Geel, N;Naeyaert, JM
通讯作者：
Naeyaert, JM
影响因子：
10.3
作者：
Jin-Su Shin;Junga Lee;S. Hann;Sang Ho Oh
通讯作者：
Jin-Su Shin;Junga Lee;S. Hann;Sang Ho Oh
影响因子：
2.4
作者：
Sklar, Lindsay R.;Burnett, Christopher T.;Ozog, David M.
通讯作者：
Ozog, David M.
影响因子：
1.2
作者：
H. Mohamed;G. Mohammed;A. H. Gomaa;M. Eyada
通讯作者：
H. Mohamed;G. Mohammed;A. H. Gomaa;M. Eyada
影响因子：
2.4
作者：
Erlendsson, Andres M.;Doukas, Apostolos G.;Haedersdal, Merete
通讯作者：
Haedersdal, Merete